After identifying several biomarkers for prenatal infection, the founders of ProteoGenix now plan to make a non-invasive amniochip that could be used to screen pregnant women for a wide range of prenatal defects, including birth defects and fetal growth restriction.
With the new amniochip, the company hopes to be able to identify prenatal infections early by simply taking a blood sample from the mother and running the processed sample through a mass spectrometer.